BIIB
Biogen Inc.
226.40$
-0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.0% | 25.6% | 25.4% | 26.5% | 24.1% | 26.6% | 27.2% | 28.1% | 30.6% | 30.5% | 31.2% | 22.8% | |
| 8.1% | 3.9% | 4.0% | 7.1% | 6.0% | 8.5% | 9.3% | 9.7% | 13.2% | 10.2% | 11.5% | 4.0% | |
| 8.1% | 3.9% | 4.0% | 7.1% | 6.0% | 8.5% | 9.3% | 9.7% | 13.6% | 13.0% | 14.5% | 4.0% | |
| 7.8% | 7.8% | 7.5% | 7.8% | 7.0% | 6.7% | 7.1% | 7.4% | 6.3% | 6.3% | 6.1% | 5.9% | |
| 10.6% | 9.4% | 9.5% | 9.3% | 8.7% | 8.8% | 8.1% | 8.0% | 7.6% | 7.4% | 6.6% | 7.4% | |
| 24.1% | 23.2% | 23.4% | 23.2% | 22.9% | 23.1% | 23.1% | 22.9% | 22.2% | 22.0% | 22.0% | 21.8% | |
| 26.1% | 31.2% | 31.2% | 30.7% | 34.6% | 34.6% | 34.2% | 33.4% | 32.0% | 31.2% | 30.7% | 42.1% | |
| 48.6% | 44.9% | 42.7% | 40.7% | 42.2% | 40.4% | 39.4% | 37.8% | 37.7% | 38.0% | 36.7% | 41.3% | |
| 17.8% | 12.8% | 12.1% | 11.6% | 19.2% | 19.7% | 18.9% | 11.2% | 11.3% | 11.4% | 10.2% | 12.2% | |
| 1.8% | 0.6% | 0.9% | 0.7% | 6.2% | 6.2% | 6.2% | – | – | 0.3% | – | 2.5% | |
| 1.6% | 1.5% | 1.5% | 1.3% | 1.5% | 1.5% | 1.4% | 1.4% | 1.4% | 1.5% | 1.2% | 1.3% | |
| 24.1% | 25.3% | 23.7% | 23.5% | 16.1% | 16.2% | 16.2% | 22.2% | 21.5% | 21.4% | 21.3% | 22.7% | |
| 51.4% | 55.1% | 57.3% | 59.3% | 57.8% | 59.6% | 60.6% | 62.2% | 62.3% | 62.0% | 63.3% | 58.7% | |
| 61.6% | 65.7% | 67.8% | 69.4% | 67.1% | 68.7% | 69.6% | 71.1% | 70.5% | 69.8% | 70.8% | 65.4% | |
| 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.